An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels [Indevus Pharmaceuticals] for the prevention of vaginally acquired HIV infection.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRO 2000 (Primary)
Indications HIV infections
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Endo Pharmaceuticals Solutions

Most Recent Events

20 Sep 2010 Results have been reported in the September 20, 2010 online issue of the Lancet.
16 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
14 Dec 2009 The results of this trial were announced by AVAC in a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight